Skip to content

Early Erectile Function Recovery, Penile Shortening, and Peyronie’s Disease After Retzius-sparing Versus Standard Robot-assisted Radical Prostatectomy

Impact of Retzius-sparing Versus Standard Robotic-assisted Radical Prostatectomy on Sexual Function: A Retrospective Cohort Study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600123541
Enrollment
Unknown
Registered
2026-04-27
Start date
2026-04-29
Completion date
Unknown
Last updated
2026-05-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostate cancer

Interventions

S-RARP group:None
RS-RARP group:None

Sponsors

The First Affiliated Hospital of Fujian Medical University
Lead Sponsor

Eligibility

Sex/Gender
Male

Inclusion criteria

Inclusion criteria: 1. Male patients with normal baseline sexual function (IIEF-5 score of 22–25), who had not used phosphodiesterase type 5 (PDE5) inhibitors or any other pharmacological or device-based interventions (as determined from patient self-report or clinical records); 2. No self-reported urinary incontinence; 3. Histologically confirmed diagnosis of prostate cancer by biopsy; 4. Localized prostate cancer (clinical stage cT1–T3N0M0); 5. Eligible for robot-assisted radical prostatectomy (RARP); 6. Complete preoperative and postoperative follow-up data, with a minimum follow-up duration of 12 months; 7. Provided written informed consent and agreed to participate in the study.

Exclusion criteria

Exclusion criteria: 1. History of pelvic radiotherapy, open or laparoscopic prostate surgery, or hormonal therapy for prostate cancer; 2. Presence of severe neurogenic bladder, overactive bladder, or urethral sphincter dysfunction; 3. Presence of moderate-to-severe cognitive impairment or psychiatric disorders that preclude compliance with follow-up assessments; 4. Intraoperative findings of tumor invasion of the bladder neck or urethra, or extensive pelvic lymph node metastasis; 5. Severe comorbidities (e.g., severe cardiopulmonary insufficiency) rendering the patient unfit for surgery; 6. Loss to follow-up or incomplete data during the postoperative follow-up period.

Design outcomes

Primary

MeasureTime frame
Postoperative erectile function;IIEF-6 at 12 months postoperatively;Postoperative penile shortening;Postoperative peyronie’s disease;

Secondary

MeasureTime frame
PSA persistence;Biochemical recurrence;Adjuvant treatment;Surgical margin status;Operation related indicators;

Countries

China

Contacts

Public ContactNing Xu

The First Affiliated Hospital of Fujian Medical University

drxun@fjmu.edu.cn+86 132 3590 7575

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: May 7, 2026